Literature DB >> 9759882

A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.

R F Wang1, S L Johnston, G Zeng, S L Topalian, D J Schwartzentruber, S A Rosenberg.   

Abstract

Infusion of TIL586 along with IL-2 into the autologous patient with metastatic melanoma resulted in the objective regression of tumor. Here, we report that screening a cDNA library from the 586mel cell line using CTL clones derived from TIL586 resulted in the isolation of a gene, CAG-3 (cancer Ag gene 3). Sequence analysis revealed that CAG-3 encodes an open reading frame identical to NY-ESO-1, which was recently reported to be recognized by autologous serum from a patient with esophageal cancer. Thus, NY-ESO-1 appears to be an immune target for both Ab- and T cell-mediated responses. Significantly, NY-ESO-1-specific CTL clones were capable of recognizing two HLA-A31-positive fresh and cultured breast tumors. To our knowledge, this represents the first direct demonstration that tumor-specific CTL clones can recognize both breast and melanoma tumor cells. A 10-mer antigenic peptide ESO10-53 (ASGPGGGAPR) was identified from the normal open reading frame of NY-ESO-1 based on its ability to sensitize HLA-A31-positive target cells for cytokine release and specific lysis. Interestingly, two additional CTL clones that were sensitized with NY-ESO-1 recognized two overlapping antigenic peptides derived from an alternative open reading frame of the same gene. These findings indicate that CTLs simultaneously responded to two different gene products translated from the normal and alternative reading frames of the same gene. Understanding of this mechanism by which the alternative reading frame is translated may have important implications in tumor immunology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759882

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

2.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

3.  Development of effective immunotherapy for the treatment of patients with cancer.

Authors:  Steven A Rosenberg
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

Review 4.  Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing.

Authors:  Ken-ichi Hanada; James C Yang
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

5.  Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

Authors:  Midori Isobe; Shingo Eikawa; Akiko Uenaka; Yoichi Nakamura; Tetsuo Kanda; Shigeru Kohno; Kiyotaka Kuzushima; Eiichi Nakayama
Journal:  Cancer Immun       Date:  2009-10-01

6.  Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.

Authors:  Yinin Hu; Gina R Petroni; Walter C Olson; Andrea Czarkowski; Mark E Smolkin; William W Grosh; Kimberly A Chianese-Bullock; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2014-04-23       Impact factor: 6.968

7.  A special issue on cancer immunotherapy.

Authors:  Rong-Fu Wang
Journal:  Cell Res       Date:  2017-01       Impact factor: 25.617

Review 8.  Progress in the development of immunotherapy for the treatment of patients with cancer.

Authors:  S A Rosenberg
Journal:  J Intern Med       Date:  2001-12       Impact factor: 8.989

9.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

10.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

Authors:  Ian D Davis; Weisan Chen; Heather Jackson; Phillip Parente; Mark Shackleton; Wendie Hopkins; Qiyuan Chen; Nektaria Dimopoulos; Tina Luke; Roger Murphy; Andrew M Scott; Eugene Maraskovsky; Grant McArthur; Duncan MacGregor; Sue Sturrock; Tsin Yee Tai; Simon Green; Andrew Cuthbertson; Darryl Maher; Lena Miloradovic; Susan V Mitchell; Gerd Ritter; Achim A Jungbluth; Yao-Tseng Chen; Sacha Gnjatic; Eric W Hoffman; Lloyd J Old; Jonathan S Cebon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.